Your browser doesn't support javascript.
Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases.
Ljungquist, Oskar; Lundgren, Maria; Iliachenko, Elena; Månsson, Fredrik; Böttiger, Blenda; Landin-Olsson, Mona; Wikén, Christian; Rosendal, Ebba; Överby, Anna K; Wigren, Byström J; Forsell, Mattias N E; Kjeldsen-Kragh, Jens; Rasmussen, Magnus; Kahn, Fredrik; Holm, Karin.
  • Ljungquist O; Department of Translational Medicine, Clinical Infection Medicine, Faculty of Medicine, Lund University, Malmö, Sweden.
  • Lundgren M; Department of Infectious Diseases, Helsingborg Hospital, Helsingborg, Sweden.
  • Iliachenko E; Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden.
  • Månsson F; Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund, Sweden.
  • Böttiger B; Department of Translational Medicine, Clinical Infection Medicine, Faculty of Medicine, Lund University, Malmö, Sweden.
  • Landin-Olsson M; Skåne University Hospital, Malmö, Sweden.
  • Wikén C; Department of Clinical Microbiology, University and Regional Laboratories, Lund, Sweden.
  • Rosendal E; Skåne University Hospital, Malmö, Sweden.
  • Överby AK; Department of Clinical Science, Division of Internal Medicine, Lund University, Lund, Sweden.
  • Wigren BJ; Skåne University Hospital, Malmö, Sweden.
  • Forsell MNE; Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden.
  • Kjeldsen-Kragh J; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  • Rasmussen M; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  • Kahn F; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  • Holm K; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
Infect Dis (Lond) ; 54(4): 283-291, 2022 04.
Article in English | MEDLINE | ID: covidwho-1557035
ABSTRACT

BACKGROUND:

Immunosuppressed patients are particularly vulnerable to severe infection from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), risking prolonged viremia and symptom duration. In this study we describe clinical and virological treatment outcomes in a heterogeneous group of patients with severe immunosuppression due to various causes suffering from COVID-19 infection, who were all treated with convalescent plasma (CCP) along with standard treatment.

METHODS:

We performed an observational, retrospective case series between May 2020 to March 2021 at three sites in Skåne, Sweden, with a population of nearly 1.4 million people. All patients hospitalized for COVID-19 who received CCP with the indication severe immunosuppression as defined by the treating physician were included in the study (n = 28).

RESULTS:

In total, 28 severely immunocompromised patients, half of which previously had been treated with rituximab, who had received in-hospital convalescent plasma treatment of COVID-19 were identified. One week after CCP treatment, 13 of 28 (46%) patients had improved clinically defined as a decrease of at least one point at the WHO-scale. Three patients had increased score points of whom two had died. For 12 patients, the WHO-scale was unchanged.

CONCLUSION:

As one of only few studies on CCP treatment of COVID-19 in hospitalized patients with severe immunosuppression, this study adds descriptive data. The study design prohibits conclusions on safety and efficacy, and the results should be interpreted with caution. Prospective, randomized trials are needed to investigate this further.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Passive / Immunocompromised Host / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Infect Dis (Lond) Year: 2022 Document Type: Article Affiliation country: 23744235.2021.2013528

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunization, Passive / Immunocompromised Host / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Infect Dis (Lond) Year: 2022 Document Type: Article Affiliation country: 23744235.2021.2013528